

## DAFTAR PUSTAKA

- Ahsan, M., & Mallick, A. K. (2020). Is remdesivir the therapeutic answer for COVID-19: a review of current knowledge. *International Journal of Basic & Clinical Pharmacology*, 9(9), 1462. <https://doi.org/10.18203/2319-2003.ijbcp20203636>
- Ambrus, C., Bakos, É., Sarkadi, B., Özvegy-Laczka, C., & Telbisz, Á. (2021). Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. *Scientific Reports*, 11(1), 1–10. <https://doi.org/10.1038/s41598-021-97160-3>
- Anonim. (2020a). *Banyumas Tanggap COVID-19*. <http://covid19.banyumaskab.go.id/>
- Anonim. (2020b). Informatorium of COVID-19 Drugs in Indonesia. In *The Indonesian Food and Drug Authority* (Issue March).
- Baxter, K. (2010). Stockley's Drug Interactions Pocket Companion. In *Pharmaceutical Press* (8th Editio, Vol. 6, Issue 1). <https://doi.org/10.1111/j.2042-7166.2001.tb02784.x>
- Bethi, Y., Shewade, D. G., Dutta, T. K., & Gitanjali, B. (2018). Prevalence and predictors of potential drug-drug interactions in patients of internal medicine wards of a tertiary care hospital in India. *European Journal of Hospital Pharmacy*, 25(6), 317–321. <https://doi.org/10.1136/ejhp-2017-001272>
- Biancatelli, R. M. L., Congedo, V., Calvosa, L., Ciacciarelli, M., Polidoro, A., & Iuliano, L. (2019). Adverse reactions of amiodarone. *Journal of Geriatric Cardiology*, 16(7), 552–566. <https://doi.org/10.11909/j.issn.1671-5411.2019.07.004>
- Brandariz-Nuñez, D., Correas-Sanahuja, M., Guarce, E., Picón, R., García, B., & Gil, R. (2020). Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir. *Medicina Clinica*, 155(7), 281–287. <https://doi.org/10.1016/j.medcli.2020.06.026>
- Chakraborty, A., & Diwan, A. (2020). Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. *Journal of Biomedical Research & Environmental Sciences*, 1(8), 431–438. <https://doi.org/10.37871/jbres1175>

- Chiba, S. (2020). *Effect of Early Oseltamivir on COVID-19-Suspected Outpatients without Hypoxia*. 1–20. <https://doi.org/10.21203/rs.3.rs-33046/v1>
- Davies, B. E. (2010). Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. *The Journal of Antimicrobial Chemotherapy*, 65 Suppl 2, 5–10. <https://doi.org/10.1093/jac/dkq015>
- Deb, S., Reeves, A. A., Hopefl, R., & Bejusca, R. (2021). Adme and pharmacokinetic properties of remdesivir: Its drug interaction potential. *Pharmaceuticals*, 14(7). <https://doi.org/10.3390/ph14070655>
- Demir, E., Sütcüoğlu, O., Demir, B., Ünsal, O., & Yazıcı, O. (2021). A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma. *Journal of Oncology Pharmacy Practice*. <https://doi.org/10.1177/10781552211031304>
- Diksis, N., Melaku, T., Assefa, D., & Tesfaye, A. (2019). Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia. *SAGE Open Medicine*, 7, 205031211985735. <https://doi.org/10.1177/2050312119857353>
- DiPiro, J. T. (2011). *Edition Pharmacotherapy Handbook 8th Edition*. The McGraw-Hill.
- Dou, D., Revol, R., Östbye, H., Wang, H., & Daniels, R. (2018). Influenza A virus cell entry, replication, virion assembly and movement. *Frontiers in Immunology*, 9(JUL), 1–17. <https://doi.org/10.3389/fimmu.2018.01581>
- Duan, P., Li, S., Ai, N., Hu, L., Welsh, W. J., & You, G. (2012). Potent Inhibitors of Human Organic Anion Transporters 1 and 3 from Clinical Drug Libraries: Discovery and Molecular Characterization. *Molecular Pharmaceutics*, 9(11), 3340–3346. <https://doi.org/10.1021/mp300365t>
- Farooqui, R., Hoor, T., Karim, N., & Munneer, M. (2018). Potential drug-drug interactions among patient's prescriptions collected from medicine outpatient setting. *Pakistan Journal of Medical Sciences*, 34(1), 144–148. <https://doi.org/10.12669/pjms.341.13986>
- Finch, A., & Pillans, P. (2014). P-glycoprotein and its role in drug-drug interactions. *Australian Prescriber*, 37(4), 137–139.

- <https://doi.org/10.18773/austprescr.2014.050>
- Gandhi, Z., Mansuri, Z., & Bansod, S. (2020). Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective. *SN Comprehensive Clinical Medicine*, 2(10), 1707–1708. <https://doi.org/10.1007/s42399-020-00462-2>
- Garrison, D. A., Talebi, Z., Eisenmann, E. D., Sparreboom, A., & Baker, S. D. (2020). Role of oatp1b1 and oatp1b3 in drug-drug interactions mediated by tyrosine kinase inhibitors. *Pharmaceutics*, 12(9), 1–18. <https://doi.org/10.3390/pharmaceutics12090856>
- Gómez Moreno, G. (2020). Remdesivir-COVID-19: Drug interactions in dentistry. *European Review for Medical and Pharmacological Sciences*, 24(18), 9739–9743. [https://doi.org/10.26355/eurrev\\_202009\\_23065](https://doi.org/10.26355/eurrev_202009_23065)
- Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., Freedberg, D. E., Kirtane, A. J., Parikh, S. A., Maurer, M. S., Nordvig, A. S., Accili, D., Bathon, J. M., Mohan, S., Bauer, K. A., ... Landry, D. W. (2020). Extrapulmonary manifestations of COVID-19. *Nature Medicine*, 26(7), 1017–1032. <https://doi.org/10.1038/s41591-020-0968-3>
- Hallare, J., & Gerriets, V. (2021). *Half Life*. <https://www.ncbi.nlm.nih.gov/books/NBK554498/>
- Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R. (2021). The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. *Scientific Reports*, 11(1), 1–11. <https://doi.org/10.1038/s41598-021-90551-6>
- Humeniuk, R., Mathias, A., Kirby, B. J., Lutz, J. D., Cao, H., Osinusi, A., Babusis, D., Porter, D., Wei, X., Ling, J., Reddy, Y. S., & German, P. (2021). Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. *Clinical Pharmacokinetics*, 60(5), 569–583. <https://doi.org/10.1007/s40262-021-00984-5>
- Ito, S. (2011). Pharmacokinetics 101. *Paediatrics and Child Health*, 16(9), 535–

536. <https://doi.org/10.1093/pch/16.9.535>
- Jafari, A., Dadkhahfar, S., & Perseh, S. (2020). Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. *Critical Reviews in Oncology/Hematology*, 151(January), 102982. <https://doi.org/10.1016/j.critrevonc.2020.102982>
- Ji, Y. L., Wu, Y., Qiu, Z., Ming, H., Zhang, Y., Zhang, A. N., Leng, Y., & Xia, Z. Y. (2021). The Pathogenesis and Treatment of COVID-19: A System Review. *Biomedical and Environmental Sciences*, 34(1), 50–60. <https://doi.org/10.3967/bes2021.007>
- Jin, Y. H., Cai, L., Cheng, Z. S., Cheng, H., Deng, T., Fan, Y. P., Fang, C., Huang, D., Huang, L. Q., Huang, Q., Han, Y., Hu, B., Hu, F., Li, B. H., Li, Y. R., Liang, K., Lin, L. K., Luo, L. S., Ma, J., ... Wang, X. H. (2020). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). *Medical Journal of Chinese People's Liberation Army*, 45(1), 1–20. <https://doi.org/10.11855/j.issn.0577-7402.2020.01.01>
- Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021). Role of favipiravir in the treatment of COVID-19. *International Journal of Infectious Diseases*, 102, 501–508. <https://doi.org/10.1016/j.ijid.2020.10.069>
- Kim, S. Y., & Moon, A. (2012). Drug-induced nephrotoxicity and its biomarkers. *Biomolecules and Therapeutics*, 20(3), 268–272. <https://doi.org/10.4062/biomolther.2012.20.3.268>
- Kumar, D., & Trivedi, N. (2021). Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. *Biomedicine and Pharmacotherapy*, 139, 111642. <https://doi.org/10.1016/j.biopha.2021.111642>
- Kumar, I. (2021). A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of coronavirus disease. *Journal of Drug Delivery and Therapeutics*, 11(1), 121–129. <https://doi.org/10.22270/jddt.v11i1.4475>
- Lai, C., Shih, T.-P., Ko, W.-C., Tang, H.-J., & Hsueh, P.-R. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-

- 2019 (COVID-19): The epidemic and the challenges. *International Journal of Antimicrobial Agents*, 55(3), 105924. <https://doi.org/10.1016/j.ijantimicag.2020.105924>
- Lepist, E. I., & Ray, A. S. (2016). Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant? *Journal of Clinical Pharmacology*, 56(November 2015), S73–S81. <https://doi.org/10.1002/jcph.735>
- Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., ... Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet*, 395(10224), 565–574. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
- Ng, W. H., Tipih, T., Makoah, N. A., Vermeulen, J. G., Goedhals, D., Sempa, J. B., Burt, F. J., Taylor, A., & Mahalingam, S. (2021). Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis. *MBio*, 12(1), 1–12. <https://doi.org/10.1128/mBio.03647-20>
- NICE. (2021). *COVID-19 rapid guideline: managing COVID-19. March*.
- Nies, A. T., König, J., Hofmann, U., Kölz, C., Fromm, M. F., & Schwab, M. (2021). Interaction of remdesivir with clinically relevant hepatic drug uptake transporters. *Pharmaceutics*, 13(3), 1–8. <https://doi.org/10.3390/pharmaceutics13030369>
- Niu, J., Straubinger, R. M., & Mager, D. E. (2019). Pharmacodynamic Drug-Drug Interactions. *Clin Pharmacol Ther.*, doi:10.1002/cpt.1434.
- PDPI. (2020). Tatalaksana Pasien Covid-19. *Perhimpunan Dokter Paru Indonesia*, 19, 19–21.
- Rahimi, M. M., Jahantabi, E., Lotfi, B., Forouzesh, M., Valizadeh, R., & Farshid, S. (2021). Renal and liver injury following the treatment of covid-19 by remdesivir. *Journal of Nephropathology*, 10(2), 1–4. <https://doi.org/10.34172/jnp.2021.10>
- Saber-Moghaddam, N., Hejazi, S., & Elyasi, S. (2021). Potential Drug–Drug Interactions among Hospitalized COVID-19 Patients Admitted to Medical

- Wards of a Referral Hospital, North-East of Iran: A Cross Sectional Study. *Journal of Pharmaceutical Care*, 3. <https://doi.org/10.18502/jpc.v9i2.6612>
- Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., Hosein, Z., Padda, I., Mangat, J., & Altaf, M. (2020). Comorbidity and its Impact on Patients with COVID-19. *SN Comprehensive Clinical Medicine*, 2(8), 1069–1076. <https://doi.org/10.1007/s42399-020-00363-4>
- Seah, T. C., Tay, Y. L., Tan, H. K., Muhammad, T. S. T., Wahab, H. A., & Tan, M. L. (2015). Determination of CYP3A4 inducing properties of compounds using a laboratory-developed cell-based assay. *International Journal of Toxicology*, 34(5), 454–468. <https://doi.org/10.1177/1091581815599335>
- Shah, S. B., Hariharan, U., & Chawla, R. (2021). Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents. *Journal of Anaesthesiology Clinical Pharmacology*. [https://doi.org/https://doi.org/10.4103/joacp.JOACP\\_461\\_20](https://doi.org/https://doi.org/10.4103/joacp.JOACP_461_20)
- Snyder, B. D., Polasek, T. M., & Doogue, M. P. (2012). Drug interactions: Principles and practice. *Australian Prescriber*, 35(3), 85–88. <https://doi.org/10.18773/austprescr.2012.037>
- Spanakis, M., Patelarou, A., Patelarou, E., & Tzanakis, N. (2021). Drug interactions for patients with respiratory diseases receiving covid-19 emerged treatments. *International Journal of Environmental Research and Public Health*, 18(21). <https://doi.org/10.3390/ijerph182111711>
- Surmelioglu, N. (2020). COVID-19 Drug Interactions. *J Crit Intensive Care*, 11(7), 43–45.
- Tan, Q., Duan, L., Ma, Y. L., Wu, F., Huang, Q., Mao, K., Xiao, W., Xia, H., Zhang, S., Zhou, E., Ma, P., Song, S., Li, Y. M., Zhao, Z., Sun, Y., Li, Z., Geng, W., Yin, Z., & Jin, Y. (2020). Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. *Bioorganic Chemistry*, 104(January), 337–339. <https://doi.org/10.1016/j.bioorg.2020.104257>
- Tanzi, M. G. (2020). FDA warns of potential drug interaction with remdesivir. *Pharmacy Today*, 26(9), 8. <https://doi.org/10.1016/j.ptdy.2020.08.024>
- Thomas, L., Birangal, S. R., Ray, R., Sekhar Miraj, S., Munisamy, M., Varma, M.,

- Chidananda, C. S., Banerjee, M., Shenoy, G. G., & Rao, M. (2021). Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data. *Therapeutic Advances in Drug Safety*, 12, 1–29. <https://doi.org/10.1177/20420986211041277>
- Wessler, J. D., Grip, L. T., Mendell, J., & Giugliano, R. P. (2013). The P-glycoprotein transport system and cardiovascular drugs. *Journal of the American College of Cardiology*, 61(25), 2495–2502. <https://doi.org/10.1016/j.jacc.2013.02.058>
- WHO. (2019). *Medication Safety in Polypharmacy: Technical Report*.
- WHO. (2021). *WHO Coronavirus Disease (COVID-19) Dashboard*. <https://covid19.who.int/>
- Wile, D. (2012). Diuretics: A review. *Annals of Clinical Biochemistry*, 49(5), 419–431. <https://doi.org/10.1258/acb.2011.011281>
- Wu, R., Wang, L., Kuo, H. C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., Poiani, G. J., Amorosa, L., Brunetti, L., & Kong, A. N. (2020). An Update on Current Therapeutic Drugs Treating COVID-19. *Current Pharmacology Reports*, 6(3), 56–70. <https://doi.org/10.1007/s40495-020-00216-7>
- Yin, J., & Wang, J. (2016). Renal drug transporters and their significance in drug-drug interactions. *Acta Pharmaceutica Sinica B*, 6(5), 363–373. <https://doi.org/10.1016/j.apsb.2016.07.013>
- Zhang, H., Wu, Y., He, Y., Liu, X., Liu, M., Tang, Y., Li, X., Yang, G., Liang, G., Xu, S., Wang, M., & Wang, W. (2022). Age-Related Risk Factors and Complications of Patients With COVID-19: A Population-Based Retrospective Study. *Frontiers in Medicine*, 8(January), 1–12. <https://doi.org/10.3389/fmed.2021.757459>
- Zhao, Y., Harmatz, J. S., Epstein, C. R., Nakagawa, Y., Kurosaki, C., Nakamura, T., Kadota, T., Giesing, D., Court, M. H., & Greenblatt, D. J. (2015). Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. *British Journal of Clinical Pharmacology*, 80(5), 1076–1085. <https://doi.org/10.1111/bcp.12644>

Zhou, Y. W., Xie, Y., Tang, L. S., Pu, D., Zhu, Y. J., Liu, J. Y., & Ma, X. L. (2021). Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. *Signal Transduction and Targeted Therapy*, 6(1). <https://doi.org/10.1038/s41392-021-00733-x>

